Gilead Sciences INC (GILD) Stock Price Declined While First Manhattan Company Boosted Its Stake

June 20, 2017 - By Nellie Frank

Investors sentiment decreased to 0.7 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3. It fall, as 106 investors sold GILD shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Ipg Advsrs Llc holds 8,046 shares. Hbk Sorce Advisory Limited Liability Company owns 12,443 shares. Louisiana State Employees Retirement holds 0.31% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 82,800 shares. D L Carlson Inv Grp reported 0.44% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cfo4life LP has invested 0.65% in Gilead Sciences, Inc. (NASDAQ:GILD). Badgley Phelps Bell has 1.21% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 194,641 shares. Stillwater Invest Mgmt Ltd Llc owns 36,614 shares. 26,495 are owned by Verition Fund Mgmt Ltd. 150,000 were reported by Selz Capital. Suntrust Banks Incorporated owns 267,568 shares. Wellington Shields Mngmt Lc owns 5,667 shares. Dock Street Asset Management holds 57,354 shares. First National Trust holds 24,787 shares. Affinity Investment Advsr Llc has 159,227 shares. Covington Cap reported 0.37% in Gilead Sciences, Inc. (NASDAQ:GILD).

Since January 3, 2017, it had 0 insider buys, and 11 insider sales for $33.68 million activity. Another trade for 20,365 shares valued at $1.41 million was made by WILSON GAYLE E on Thursday, February 23. 73,333 shares were sold by MARTIN JOHN C, worth $5.16M on Wednesday, March 1. Cogan John Francis sold $668,667 worth of stock. Another trade for 5,000 shares valued at $341,529 was made by Alton Gregg H on Monday, May 1.

First Manhattan Company increased its stake in Gilead Sciences Inc (GILD) by 3.04% based on its latest 2016Q4 regulatory filing with the SEC. First Manhattan Company bought 79,101 shares as the company’s stock declined 8.05% while stock markets rallied. The hedge fund held 2.68 million shares of the health care company at the end of 2016Q4, valued at $192.20M, up from 2.60 million at the end of the previous reported quarter. First Manhattan Company who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $85.63B market cap company. The stock rose 0.26% or $0.17 reaching $64.99 per share. About 2,964 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 20, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

First Manhattan Company, which manages about $20.51B and $16.44 billion US Long portfolio, decreased its stake in Anheuser Busch Inbev (NYSE:BUD) by 62,109 shares to 2.43M shares, valued at $255.82 million in 2016Q4, according to the filing. It also reduced its holding in Diageo P L C (NYSE:DEO) by 50,530 shares in the quarter, leaving it with 31,694 shares, and cut its stake in Wells Fargo & Co (NYSE:WFC).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: “Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2017” on June 13, 2017, also with their article: “Gilead Sciences, Inc.: The Bear Case From a Bull” published on June 09, 2017, published: “Should Gilead Buy Tesaro?” on June 13, 2017. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: and their article: “Gilead’s Oncology Pipeline: An Assessment” published on June 13, 2017 as well as‘s news article titled: “Gilead Sciences Is A Buy” with publication date: June 13, 2017.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 27 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 9 Hold. Therefore 67% are positive. Gilead Sciences had 65 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Wednesday, October 28. Citigroup initiated the shares of GILD in report on Thursday, February 25 with “Buy” rating. The firm has “Outperform” rating given on Friday, February 5 by Leerink Swann. The firm has “Outperform” rating given on Wednesday, November 2 by BMO Capital Markets. The company was downgraded on Friday, October 2 by Morgan Stanley. Berenberg initiated the stock with “Buy” rating in Thursday, September 22 report. Oppenheimer maintained the shares of GILD in report on Wednesday, July 29 with “Outperform” rating. The firm has “Outperform” rating given on Wednesday, February 3 by RBC Capital Markets. The rating was maintained by Maxim Group on Tuesday, May 30 with “Hold”. The firm has “Equal-Weight” rating given on Thursday, May 26 by Morgan Stanley.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.